English

Vascular Biogenics Ltd.

EDGAR

NTBL Quarterly report (10-Q) · filed 2024-08-14

131 filing records in this dataset, filed from 2014-06-06 to 2024-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

2 thousand USD

2024 Q2 · USD

Exact inputs and evidence

Revenue: 2000 USD Source

Operating margin

-269,000%

2024 Q2 · %

Exact inputs and evidence

Operating Income: -5380000 USD Source
Revenue: 2000 USD Source

Operating cash flow

-3.71 million USD

2024 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -7271000 USD Source
Operating Cash Flow: -3561000 USD Source

Free cash flow

-3.72 million USD

2024 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -7271000 USD Source
Operating Cash Flow: -3561000 USD Source
Capital Expenditure: 14000 USD Source
Capital Expenditure: 6000 USD Source

Cash and cash equivalents: 4.1 million USD 2024-06-30 Source
Exact value

4100000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 9.66 million shares 2024-06-30 Source
Exact value

9659496 shares

Reported share-count change

-86.30% · -60.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

70500117 shares · 2023-06-30· Source
9659496 shares · 2024-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-16.7 million USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Net income: -1067000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -11264000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -4580000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -3766000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -5219000 USD · 2024-04-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-08-14.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2023-12-31
Operating income: 9 of 11 periods available· newest 2023-12-31
Net income: 6 of 11 periods available· newest 2023-12-31
Operating cash flow: 9 of 11 periods available· newest 2023-12-31
Capital expenditure: 9 of 11 periods available· newest 2023-12-31
Total assets: 7 of 11 periods available· newest 2023-12-31
Total liabilities: 7 of 11 periods available· newest 2023-12-31
Current assets: 7 of 11 periods available· newest 2023-12-31
Current liabilities: 7 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+3,775%

Prior period

USD 8,000

2022-01-01 – 2022-12-31
Current period

USD 310,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

310000 − 8000 = 302000 USD

8000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
310000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Year-over-year change in Revenue: 302000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 310000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2292066 Filing: 000149315224024541 Input fundies:Revenue: 8000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2292962 Filing: 000149315224024541
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 3.14 million

Prior period

−USD 14.41 million

2022-01-01 – 2022-12-31
Current period

−USD 11.26 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-11264000 − -14407000 = 3143000 USD

-14407000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-11264000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Year-over-year change in Net income: 3143000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -11264000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#3407040 Filing: 000149315224024541 Input fundies:NetIncome: -14407000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#3408019 Filing: 000149315224024541
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.07 million

Prior period

−USD 11.64 million

2022-01-01 – 2022-12-31
Current period

−USD 13.72 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-13716000 − -11642000 = -2074000 USD

-11642000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-13716000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Year-over-year change in Operating cash flow: -2074000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -13716000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2669813 Filing: 000149315224024541 Input fundies:OperatingCashFlow: -11642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2670736 Filing: 000149315224024541
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+58.5%

Prior period

USD 41,000

2022-01-01 – 2022-12-31
Current period

USD 65,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

65000 − 41000 = 24000 USD

41000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
65000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Year-over-year change in Capital expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 65000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2675263 Filing: 000149315224024541 Input fundies:CapitalExpenditure: 41000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2676105 Filing: 000149315224024541
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 310,000 100% of revenue
Cost of revenue USD 197,000 64% of revenue
Operating expenses USD 14.77 million 4,765% of revenue
Operating income −USD 14.66 million −4,728% of revenue
Tax, interest and other Derived −USD 3.39 million −1,095% of revenue
Net income −USD 11.26 million −3,634% of revenue

Cash

Operating cash flow −USD 13.72 million −4,425% of revenue
Capital expenditure USD 65,000 21% of revenue
Free cash flow Derived −USD 13.78 million −4,445% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Not shown: operating income or net income is not reported.
2018 Net income was higher than operating income, so the split is not drawn.
2019 Operating loss: operating costs were 3,673% of revenue.
2020 Operating loss: operating costs were 2,755% of revenue.
2021 Operating loss: operating costs were 4,006% of revenue.
2022 Operating loss: operating costs were 161,650% of revenue.
2023 Operating loss: operating costs were 4,828% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	13864000	3726000 Derived	10138000	Unavailable	Unavailable	-10303000 Derived	Source 2017-01-01 – 2017-12-31: 13864000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 10138000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -3821000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 6482000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	585000	-20660000 Derived	21245000	749000 Derived	20496000	-17909000 Derived	Source 2018-01-01 – 2018-12-31: 585000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 21245000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 20496000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -15680000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2229000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	562000	20644000 Derived	-20082000	-686000 Derived	-19396000	-13162000 Derived	Source 2019-01-01 – 2019-12-31: 562000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -20082000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -19396000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -13089000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 73000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	922000	25405000 Derived	-24483000	-258000 Derived	-24225000	-23429000 Derived	Source 2020-01-01 – 2020-12-31: 922000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -24483000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -24225000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -23378000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 51000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	768000	30764000 Derived	-29996000	-76000 Derived	-29920000	-26449000 Derived	Source 2021-01-01 – 2021-12-31: 768000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -29996000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -29920000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -24984000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1465000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	8000	12932000 Derived	-12924000	1483000 Derived	-14407000	-11683000 Derived	Source 2022-01-01 – 2022-12-31: 8000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -12924000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -14407000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -11642000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 41000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	310000	14967000 Derived	-14657000	-3393000 Derived	-11264000	-13781000 Derived	Source 2023-01-01 – 2023-12-31: 310000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -14657000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -11264000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -13716000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 65000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 310K 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	13864000	Revenue: 13864000 Open source
20182018-12-31	Revenue	585000	Revenue: 585000 Open source
20192019-12-31	Revenue	562000	Revenue: 562000 Open source
20202020-12-31	Revenue	922000	Revenue: 922000 Open source
20212021-12-31	Revenue	768000	Revenue: 768000 Open source
20222022-12-31	Revenue	8000	Revenue: 8000 Open source
20232023-12-31	Revenue	310000	Revenue: 310000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

3,775% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 13864000 Open source
20182018-12-31	Year over year	-95.8%	Revenue: 585000 Open source Revenue: 13864000 Open source
20192019-12-31	Year over year	-3.9%	Revenue: 562000 Open source Revenue: 585000 Open source
20202020-12-31	Year over year	64.1%	Revenue: 922000 Open source Revenue: 562000 Open source
20212021-12-31	Year over year	-16.7%	Revenue: 768000 Open source Revenue: 922000 Open source
20222022-12-31	Year over year	-99%	Revenue: 8000 Open source Revenue: 768000 Open source
20232023-12-31	Year over year	3,775%	Revenue: 310000 Open source Revenue: 8000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,728.1% 2023

Net margin -3,633.5% 2023

Free cash flow margin -4,445.5% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	73.1%	Operating Income: 10138000 Open source Revenue: 13864000 Open source
20182018-12-31	Operating margin	3,631.6%	Operating Income: 21245000 Open source Revenue: 585000 Open source
20192019-12-31	Operating margin	-3,573.3%	Operating Income: -20082000 Open source Revenue: 562000 Open source
20202020-12-31	Operating margin	-2,655.4%	Operating Income: -24483000 Open source Revenue: 922000 Open source
20212021-12-31	Operating margin	-3,905.7%	Operating Income: -29996000 Open source Revenue: 768000 Open source
20222022-12-31	Operating margin	-161,550%	Operating Income: -12924000 Open source Revenue: 8000 Open source
20232023-12-31	Operating margin	-4,728.1%	Operating Income: -14657000 Open source Revenue: 310000 Open source
2017-12-31	Net margin	Not reported	Revenue: 13864000 Open source
20182018-12-31	Net margin	3,503.6%	Net Income: 20496000 Open source Revenue: 585000 Open source
20192019-12-31	Net margin	-3,451.2%	Net Income: -19396000 Open source Revenue: 562000 Open source
20202020-12-31	Net margin	-2,627.4%	Net Income: -24225000 Open source Revenue: 922000 Open source
20212021-12-31	Net margin	-3,895.8%	Net Income: -29920000 Open source Revenue: 768000 Open source
20222022-12-31	Net margin	-180,087.5%	Net Income: -14407000 Open source Revenue: 8000 Open source
20232023-12-31	Net margin	-3,633.5%	Net Income: -11264000 Open source Revenue: 310000 Open source
20172017-12-31	Free cash flow margin	-74.3%	Revenue: 13864000 Open source Operating Cash Flow: -3821000 Open source Capital Expenditure: 6482000 Open source
20182018-12-31	Free cash flow margin	-3,061.4%	Revenue: 585000 Open source Operating Cash Flow: -15680000 Open source Capital Expenditure: 2229000 Open source
20192019-12-31	Free cash flow margin	-2,342%	Revenue: 562000 Open source Operating Cash Flow: -13089000 Open source Capital Expenditure: 73000 Open source
20202020-12-31	Free cash flow margin	-2,541.1%	Revenue: 922000 Open source Operating Cash Flow: -23378000 Open source Capital Expenditure: 51000 Open source
20212021-12-31	Free cash flow margin	-3,443.9%	Revenue: 768000 Open source Operating Cash Flow: -24984000 Open source Capital Expenditure: 1465000 Open source
20222022-12-31	Free cash flow margin	-146,037.5%	Revenue: 8000 Open source Operating Cash Flow: -11642000 Open source Capital Expenditure: 41000 Open source
20232023-12-31	Free cash flow margin	-4,445.5%	Revenue: 310000 Open source Operating Cash Flow: -13716000 Open source Capital Expenditure: 65000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -13.7M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-3821000	Operating Cash Flow: -3821000 Open source
20182018-12-31	Operating cash flow	-15680000	Operating Cash Flow: -15680000 Open source
20192019-12-31	Operating cash flow	-13089000	Operating Cash Flow: -13089000 Open source
20202020-12-31	Operating cash flow	-23378000	Operating Cash Flow: -23378000 Open source
20212021-12-31	Operating cash flow	-24984000	Operating Cash Flow: -24984000 Open source
20222022-12-31	Operating cash flow	-11642000	Operating Cash Flow: -11642000 Open source
20232023-12-31	Operating cash flow	-13716000	Operating Cash Flow: -13716000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -13.8M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-10303000	Operating Cash Flow: -3821000 Open source Capital Expenditure: 6482000 Open source
20182018-12-31	Free cash flow	-17909000	Operating Cash Flow: -15680000 Open source Capital Expenditure: 2229000 Open source
20192019-12-31	Free cash flow	-13162000	Operating Cash Flow: -13089000 Open source Capital Expenditure: 73000 Open source
20202020-12-31	Free cash flow	-23429000	Operating Cash Flow: -23378000 Open source Capital Expenditure: 51000 Open source
20212021-12-31	Free cash flow	-26449000	Operating Cash Flow: -24984000 Open source Capital Expenditure: 1465000 Open source
20222022-12-31	Free cash flow	-11683000	Operating Cash Flow: -11642000 Open source Capital Expenditure: 41000 Open source
20232023-12-31	Free cash flow	-13781000	Operating Cash Flow: -13716000 Open source Capital Expenditure: 65000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

22.7% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	14.9%	Total Liabilities: 9789000 Open source Total Assets: 65689000 Open source
20182018-12-31	Liabilities / assets	12.5%	Total Liabilities: 7585000 Open source Total Assets: 60678000 Open source
20192019-12-31	Liabilities / assets	26.5%	Total Liabilities: 12982000 Open source Total Assets: 49005000 Open source
20202020-12-31	Liabilities / assets	25.9%	Total Liabilities: 10789000 Open source Total Assets: 41706000 Open source
20212021-12-31	Liabilities / assets	19.3%	Total Liabilities: 12483000 Open source Total Assets: 64661000 Open source
20222022-12-31	Liabilities / assets	129.3%	Total Liabilities: 7127000 Open source Total Assets: 5511000 Open source
20232023-12-31	Liabilities / assets	22.7%	Total Liabilities: 4427000 Open source Total Assets: 19541000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.65× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	7.72×	Current Assets: 58458000 Open source Current Liabilities: 7569000 Open source
20182018-12-31	Current assets / current liabilities	10.83×	Current Assets: 51709000 Open source Current Liabilities: 4774000 Open source
20192019-12-31	Current assets / current liabilities	4.36×	Current Assets: 37777000 Open source Current Liabilities: 8666000 Open source
20202020-12-31	Current assets / current liabilities	4.29×	Current Assets: 31993000 Open source Current Liabilities: 7459000 Open source
20212021-12-31	Current assets / current liabilities	5.53×	Current Assets: 54847000 Open source Current Liabilities: 9926000 Open source
20222022-12-31	Current assets / current liabilities	1.48×	Current Assets: 2988000 Open source Current Liabilities: 2014000 Open source
20232023-12-31	Current assets / current liabilities	5.65×	Current Assets: 15470000 Open source Current Liabilities: 2738000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	Unavailable Not reported for this period.	−USD 13.2 million Exact value Exact value: -13203000 USD 2015-01-01 – 2015-12-31: -13203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2015-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -13203000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13203000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml#249373 Filing: 000149315218003377 The citation records this snapshot. The page link may show a newer release later.	USD 90,000 Exact value Exact value: 90000 USD 2015-01-01 – 2015-12-31: 90000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2015-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 90000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 90000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml#249974 Filing: 000149315218003377 The citation records this snapshot. The page link may show a newer release later.	−USD 13.29 million Calculation and evidence -13203000 − 90000 USD Exact free cash flow: -13293000 USD 2015-01-01 – 2015-12-31: -13203000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 90000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2015-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -13293000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13203000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml#249373 Filing: 000149315218003377 Input fundies:CapitalExpenditure: 90000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml#249974 Filing: 000149315218003377 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−USD 13.41 million Exact value Exact value: -13412000 USD 2016-01-01 – 2016-12-31: -13412000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2016-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -13412000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13412000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315219004066/vblt-20181231.xml#268089 Filing: 000149315219004066 The citation records this snapshot. The page link may show a newer release later.	USD 491,000 Exact value Exact value: 491000 USD 2016-01-01 – 2016-12-31: 491000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2016-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 491000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 491000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315219004066/vblt-20181231.xml#268692 Filing: 000149315219004066 The citation records this snapshot. The page link may show a newer release later.	−USD 13.9 million Calculation and evidence -13412000 − 491000 USD Exact free cash flow: -13903000 USD 2016-01-01 – 2016-12-31: -13412000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 491000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2016-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -13903000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13412000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315219004066/vblt-20181231.xml#268089 Filing: 000149315219004066 Input fundies:CapitalExpenditure: 491000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315219004066/vblt-20181231.xml#268692 Filing: 000149315219004066 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 3.82 million Exact value Exact value: -3821000 USD 2017-01-01 – 2017-12-31: -3821000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2017-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -3821000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3821000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315220004312/vblt-20191231.xml#247587 Filing: 000149315220004312 The citation records this snapshot. The page link may show a newer release later.	USD 6.48 million Exact value Exact value: 6482000 USD 2017-01-01 – 2017-12-31: 6482000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2017-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 6482000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6482000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315220004312/vblt-20191231.xml#248135 Filing: 000149315220004312 The citation records this snapshot. The page link may show a newer release later.	−USD 10.3 million Calculation and evidence -3821000 − 6482000 USD Exact free cash flow: -10303000 USD 2017-01-01 – 2017-12-31: -3821000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 6482000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2017-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -10303000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3821000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315220004312/vblt-20191231.xml#247587 Filing: 000149315220004312 Input fundies:CapitalExpenditure: 6482000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315220004312/vblt-20191231.xml#248135 Filing: 000149315220004312 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 20.5 million Exact value Exact value: 20496000 USD 2018-01-01 – 2018-12-31: 20496000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2018-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: 20496000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 20496000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315221006761/vblt-20201231.xml#150718 Filing: 000149315221006761 The citation records this snapshot. The page link may show a newer release later.	−USD 15.68 million Exact value Exact value: -15680000 USD 2018-01-01 – 2018-12-31: -15680000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2018-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -15680000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15680000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315221006761/vblt-20201231.xml#178543 Filing: 000149315221006761 The citation records this snapshot. The page link may show a newer release later.	USD 2.23 million Exact value Exact value: 2229000 USD 2018-01-01 – 2018-12-31: 2229000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2018-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 2229000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2229000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315221006761/vblt-20201231.xml#654591 Filing: 000149315221006761 The citation records this snapshot. The page link may show a newer release later.	−USD 17.91 million Calculation and evidence -15680000 − 2229000 USD Exact free cash flow: -17909000 USD 2018-01-01 – 2018-12-31: -15680000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2229000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2018-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -17909000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15680000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315221006761/vblt-20201231.xml#178543 Filing: 000149315221006761 Input fundies:CapitalExpenditure: 2229000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315221006761/vblt-20201231.xml#654591 Filing: 000149315221006761 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 19.4 million Exact value Exact value: -19396000 USD 2019-01-01 – 2019-12-31: -19396000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2019-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: -19396000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19396000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#2329822 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	−USD 13.09 million Exact value Exact value: -13089000 USD 2019-01-01 – 2019-12-31: -13089000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2019-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -13089000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13089000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1767163 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	USD 73,000 Exact value Exact value: 73000 USD 2019-01-01 – 2019-12-31: 73000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2019-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 73000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 73000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1769624 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	−USD 13.16 million Calculation and evidence -13089000 − 73000 USD Exact free cash flow: -13162000 USD 2019-01-01 – 2019-12-31: -13089000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 73000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2019-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -13162000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13089000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1767163 Filing: 000149315222007493 Input fundies:CapitalExpenditure: 73000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1769624 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 24.23 million Exact value Exact value: -24225000 USD 2020-01-01 – 2020-12-31: -24225000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2020-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: -24225000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24225000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#2329392 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	−USD 23.38 million Exact value Exact value: -23378000 USD 2020-01-01 – 2020-12-31: -23378000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2020-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -23378000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23378000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1766760 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	USD 51,000 Exact value Exact value: 51000 USD 2020-01-01 – 2020-12-31: 51000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2020-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 51000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1769297 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.	−USD 23.43 million Calculation and evidence -23378000 − 51000 USD Exact free cash flow: -23429000 USD 2020-01-01 – 2020-12-31: -23378000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 51000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2020-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -23429000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23378000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1766760 Filing: 000149315222007493 Input fundies:CapitalExpenditure: 51000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315222007493/form20-f.htm#1769297 Filing: 000149315222007493 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 29.92 million Exact value Exact value: -29920000 USD 2021-01-01 – 2021-12-31: -29920000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2021-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: -29920000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29920000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315223016302/forms-4.htm#4722424 Filing: 000149315223016302 The citation records this snapshot. The page link may show a newer release later.	−USD 24.98 million Exact value Exact value: -24984000 USD 2021-01-01 – 2021-12-31: -24984000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2021-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -24984000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24984000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315223016302/forms-4.htm#4249217 Filing: 000149315223016302 The citation records this snapshot. The page link may show a newer release later.	USD 1.47 million Exact value Exact value: 1465000 USD 2021-01-01 – 2021-12-31: 1465000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2021-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 1465000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1465000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315223016302/forms-4.htm#4252829 Filing: 000149315223016302 The citation records this snapshot. The page link may show a newer release later.	−USD 26.45 million Calculation and evidence -24984000 − 1465000 USD Exact free cash flow: -26449000 USD 2021-01-01 – 2021-12-31: -24984000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1465000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2021-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -26449000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24984000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315223016302/forms-4.htm#4249217 Filing: 000149315223016302 Input fundies:CapitalExpenditure: 1465000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315223016302/forms-4.htm#4252829 Filing: 000149315223016302 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 14.41 million Exact value Exact value: -14407000 USD 2022-01-01 – 2022-12-31: -14407000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2022-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: -14407000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14407000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#3408019 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	−USD 11.64 million Exact value Exact value: -11642000 USD 2022-01-01 – 2022-12-31: -11642000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2022-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -11642000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2670736 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	USD 41,000 Exact value Exact value: 41000 USD 2022-01-01 – 2022-12-31: 41000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2022-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 41000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 41000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2676105 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	−USD 11.68 million Calculation and evidence -11642000 − 41000 USD Exact free cash flow: -11683000 USD 2022-01-01 – 2022-12-31: -11642000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 41000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2022-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -11683000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2670736 Filing: 000149315224024541 Input fundies:CapitalExpenditure: 41000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2676105 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 11.26 million Exact value Exact value: -11264000 USD 2023-01-01 – 2023-12-31: -11264000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Net Income: -11264000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11264000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#3407040 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	−USD 13.72 million Exact value Exact value: -13716000 USD 2023-01-01 – 2023-12-31: -13716000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Operating Cash Flow: -13716000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13716000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2669813 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	USD 65,000 Exact value Exact value: 65000 USD 2023-01-01 – 2023-12-31: 65000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Capital Expenditure: 65000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 65000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2675263 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.	−USD 13.78 million Calculation and evidence -13716000 − 65000 USD Exact free cash flow: -13781000 USD 2023-01-01 – 2023-12-31: -13716000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 65000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vascular Biogenics Ltd. · 2023-12-31 Vascular Biogenics Ltd. (edgar:1603207) Free cash flow: -13781000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1603207?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13716000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2669813 Filing: 000149315224024541 Input fundies:CapitalExpenditure: 65000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1603207/000149315224024541/forms-1.htm#2675263 Filing: 000149315224024541 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

131 filings · 1,390 latest values · 1,390 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001603207, 1603207, NTBL, VBLT, edgar:1603207

Also known as NOTABLE LABS, LTD., Notable Labs, Ltd., Vascular Biogenics Ltd., Vascular Biogenics Ltd.

Vascular Biogenics Ltd.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation